Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update

Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update

This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-Her2 Antibodies 2016 updates the competitive landscape of biosimilar and biosuperior therapeutic antibodies targeting Her2 in comparison with originator anti-Her2 antibodies to treat solid tumors as of May 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in development of Her2 targeting antibodies for treatment of Her2 positive breast and gastric cancer. In addition, the report lists company-specific R&D pipelines of biosimilar and biosuperior Herceptin antibodies. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.